A Phase 2 interventional study of (CP-6890,550) Tofacitinib and Placebo in Plaque Psoriasis, sponsored by Pfizer. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-04-13.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing tofacitinib in Psoriasis — 4 open to participants now, 4 under way, 1 of them phase 3. tofacitinib · Psoriasis.
Among the 19 studies testing tofacitinib in Psoriasis, this one is the 18th largest by enrollment, is one of 3 that started in 2013, is one of 6 in phase 2, and was the 10th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →4 of the 19 studies testing tofacitinib in Psoriasis are open now, in 3 countries. Recruiting first, the newest first:
Lahore General Hospital · Sites in Pakistan
Ages 18–70 · Healthy volunteers
University of California, San Francisco · Sites in United States
Ages 18+
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 18+
Pak Emirates Military Hospital
Ages 18–70
By country, each count listing its studies:
tofacitinib: first FDA approval 2012 (XELJANZ), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 3 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 135 across the 19 interventional studies. Of the 15 that completed or were terminated, 15 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 19 have an industry lead sponsor. The 6 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
57 studies in Psoriasis by Pfizer: none open now, none under way, none of them phase 3. Of 56 finished, 46 (82%) have results posted.
Among the 57 studies in Psoriasis by Pfizer, this one is the 40th largest by enrollment of the 42 interventional ones that give a count, is one of 4 that started in 2013, is one of 13 in phase 2, and was the 41st registered.
Pfizer’s Psoriasis studies by the year they started, since 2002.
1 of the studies testing tofacitinib in Psoriasis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07581418Pak Emirates Military HospitalComparison of Methotrexate and Tofacitinib in Chronic Plaque Psoriasis | 2026-12-01 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing tofacitinib in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Pfizer’s 57 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
There are cells in the skin and blood of humans with chronic moderate to severe plaque psoriasis with specific activities that may determine the effectiveness of treatment. These activities may be described by obtaining samples of skin and blood and analyzing them using a variety of tests.
The final subject in Cohort 1 completed the study on 19-Nov-2013 (LSLV date). Because the study analyses were novel and exploratory, they required extensive analyses by study team and external experts. As a result of this analysis it was determined on 21-July-2014 that the data from Cohort 1 were sufficiently definitive and that enrollment of Cohort 2 would not be justified. Since this decision resulted in the LSLV for Cohort 1 becoming the LSLV for the study, the full data analysis and reporting is not projected to be complete within 12 Months of LSLV. The final analysis and final reporting is planned to be completed on 18-Feb-2015. Results for this data are anticipated to be released in April 2015.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: (CP-6890,550) Tofacitinib · Drug: Placebo
Drug: (CP-690,550) Tofacitinib · Drug: Placebo
2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 weeks
2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
Percentage of Participants Achieving a 75% Reduction in the Psoriasis Area and Severity Index (PASI75) at Week 12
Combined assessment of lesion severity and area affected into single score; range equals (=) 0 (no disease) to 72 (maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated: 0 (0%) to 6 (90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4) summed over all sections.
Time frame: Week 12
Percentage of Participants Achieving a Physician's Global Assessment (PGA) Response of "Clear" or "Almost Clear" at Week 12
PGA psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration and scaling across all psoriatic lesions. PGA of Psoriasis scale ranges from 0 (no psoriasis) to 4 (severe disease). ‘Clear’ and “Almost clear’ includes all participants who were scored as a 0 or 1.
Time frame: Week 12
Psoriasis Area and Severity Index (PASI) Score by Visit
Combined assessment of lesion severity and area affected into single score. Body was divided into 4 sections: head, arms, trunk, legs. For each section, percent area of skin involved was estimated: 0=0% to 6=90â€"100%. Severity was estimated by clinical signs: erythema, induration, desquamation; scale: 0= none to 4= maximum. Final PASI = sum of severity parameters for each section\*area score\*weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4) summed over all sections; total possible score range: 0= no disease to 72= maximal disease.
Time frame: Baseline and Weeks 1, 2, 4, and 12
Change From Baseline in PASI by Visit
Combined assessment of lesion severity and area affected into single score. Body was divided into 4 sections: head, arms, trunk, legs. For each section, percent area of skin involved was estimated: 0=0% to 6=90â€"100%. Severity was estimated by clinical signs: erythema, induration, desquamation; scale: 0= none to 4= maximum. Final PASI = sum of severity parameters for each section\*area score\*weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4) summed over all sections; total possible score range: 0= no disease to 72= maximal disease.
Time frame: Weeks 1, 2, 4 and 12
Percent Change From Baseline in PASI by Visit
Combined assessment of lesion severity and area affected into single score. Body was divided into 4 sections: head, arms, trunk, legs. For each section, percent area of skin involved was estimated: 0= 0% to 6= 90â€"100%. Severity was estimated by clinical signs: erythema, induration, desquamation; scale: 0= none to 4= maximum. Final PASI = sum of severity parameters for each section\*area score\*weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4) summed over all sections; total possible score range: 0= no disease to 72= maximal disease.
Time frame: Weeks 1, 2, 4, and 12
Percentage of Participants Achieving a PASI75 Response at Weeks 1, 2, and 4
Combined assessment of lesion severity and area affected into single score; range=0 (no disease) to 72 (maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated: 0 (0%) to 6 (90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4) summed over all sections.
Time frame: Weeks 1, 2, and 4
Change From Baseline in PGA Score by Visit
PGA psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. PGA of Psoriasis scale ranges from 0 (no psoriasis) to 4 (severe disease). The severity scores of 3 components (erythema, induration, and scaling) are averaged and rounded to the nearest whole number to determine the PGA score.
Time frame: Weeks 1, 2, 4, and 12
Percentage of Participants in Each PGA Category at Various Timepoints by Baseline Category
Time frame: Baseline and Weeks 1, 2, 4, and 12
Percentage of Participants by PGA Response Category and Timepoint
PGA psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration and scaling across all psoriatic lesions. PGA of Psoriasis scale ranges from 0 (no psoriasis) to 4 (severe disease). Response category scores: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. The severity scores of 3 components (erythema, induration, and scaling) are averaged and rounded to the nearest whole number to determine the PGA score.
Time frame: Baseline and Weeks 1, 2, 4, and 12
Body Surface Area (BSA)
Assessment of BSA with psoriasis was performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The percent surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (ie, the participant's fully extended palm, fingers and thumb together) represents approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region can be used to determine the extent (%) to which a body regions is involved with psoriasis. In each body region, the percent body region surface area with psoriasis is multiplied by the Body Region Weighting (head and neck=10%, upper limbs=5%, trunk \[including axillae and groin\]=3.33% and lower limbs \[including buttocks\]=2.5%). BSA (%)=0.1Sh + 0.2Sh+0.3St+0.4Sl, where S=body region suface area with psoriasis: h=head; u=upper limbs; t=trunk; l=lower limbs.
Time frame: Baseline and Weeks 1, 2, 4, and 12
Change From Baseline in BSA
Assessment of BSA with psoriasis was performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The percent surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (ie, the participant's fully extended palm, fingers and thumb together) represents approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region can be used to determine the extent (%) to which a body regions is involved with psoriasis. In each body region, the percent body region surface area with psoriasis is multiplied by the Body Region Weighting (head and neck=10%, upper limbs=5%, trunk \[including axillae and groin\]=3.33% and lower limbs \[including buttocks\]=2.5%). BSA (%)=0.1Sh + 0.2Sh+0.3St+0.4Sl, where S=body region suface area with psoriasis: h=head; u=upper limbs; t=trunk; l=lower limbs.
Time frame: Weeks 1, 2, 4, and 12
Percent Change From Baseline in BSA
Assessment of BSA with psoriasis was performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The percent surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (ie, the participant's fully extended palm, fingers and thumb together) represents approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region can be used to determine the extent (%) to which a body regions is involved with psoriasis. In each body region, the percent body region surface area with psoriasis is multiplied by the Body Region Weighting (head and neck=10%, upper limbs=5%, trunk \[including axillae and groin\]=3.33% and lower limbs \[including buttocks\]=2.5%). BSA (%)=0.1Sh + 0.2Sh+0.3St+0.4Sl, where S=body region suface area with psoriasis: h=head; u=upper limbs; t=trunk; l=lower limbs.
Time frame: Weeks 1, 2, 4, and 12
Itch Severity Item (ISI) Score by Visit
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single-item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends. the baseline is defined as the average of all available diary entries before Baseline/Day 1 and the in-clinic measurement on Baseline/day 1. Week 1 is the mean of daily values of study days 2 to 8 and Week 2 is the mean of daily values of study days 9 to 15.
Time frame: Baseline and Weeks 1, 2, 4, and 12
Change From Baseline in ISI by Visit
ISI, a single-item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends. The baseline is defined as the average of all available diary entries before Baseline/Day 1 and the in-clinic measurement on Baseline/Day 1. Week 1 is the mean of daily values of study days 2 to 8 and Week 2 is the mean of daily values of study days 9 to 15. A negative value indicates an improvement.
Time frame: Weeks 1, 2, 4 and 12
Target Plaque Severity Score (TPSS) by Visit
Target lesions were selected at baseline and followed for the duration of the study. Each target lesion was scored by the investigator on severity of erythema, induration, and scaling according to a 5-point (0 to 4) severity scale with a maximum sum score for a plaque of 12. The TPSS was calculated as the sum of the scores for erythema, induration, and scaling; the score can vary in increments of 1 unit from 0 to 12.
Time frame: Baseline and Weeks 1, 2, 4, and 12
Percent Change From Baseline in TPSS by Visit
Target lesions were selected at baseline and followed for the duration of the study. Each target lesion was scored by the investigator on severity of erythema, induration, and scaling according to a 5-point (0 to 4) severity scale with a maximum sum score for a plaque of 12. The TPSS was calculated as the sum of the scores for erythema, induration, and scaling; the score can vary in increments of 1 unit from 0 to 12. A negative value indicated improvment.
Time frame: Weeks 1, 2, 4, and 12
| Milestone | Tofacitinib 10 Milligrams (mg) Twice Daily (BID) | Placebo |
|---|---|---|
| Started | 9 | 3 |
| Completed | 8 | 3 |
| Not completed | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
Combined assessment of lesion severity and area affected into single score; range equals (=) 0 (no disease) to 72 (maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated: 0 (0%) to 6 (90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4) summed over all sections.
| percentage of participants | Tofacitinib 10 mg BID | Placebo |
|---|---|---|
| Percentage of Participants Achieving a 75% Reduction in the Psoriasis Area and Severity Index (PASI75) at Week 12 | 62.50 | 33.33 |
PGA psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration and scaling across all psoriatic lesions. PGA of Psoriasis scale ranges from 0 (no psoriasis) to 4 (severe disease). ‘Clear’ and “Almost clear’ includes all participants who were scored as a 0 or 1.
| percentage of participants | Tofacitinib 10 mg BID | Placebo |
|---|---|---|
| Percentage of Participants Achieving a Physician's Global Assessment (PGA) Response of "Clear" or "Almost Clear" at Week 12 | 50.00 | 33.33 |
Combined assessment of lesion severity and area affected into single score. Body was divided into 4 sections: head, arms, trunk, legs. For each section, percent area of skin involved was estimated: 0=0% to 6=90â€"100%. Severity was estimated by clinical signs: erythema, induration, desquamation; scale: 0= none to 4= maximum. Final PASI = sum of severity parameters for each section\*area score\*weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4) summed over all sections; total possible score range: 0= no disease to 72= maximal disease.
| units on a scale | Tofacitinib 10 mg BID | Placebo |
|---|---|---|
| Baseline (n=9,3) | 21.91 ± 2.86 | 23.33 ± 5.67 |
| Week 1 (n=9,3) | 17.81 ± 3.10 | 15.53 ± 6.60 |
| Week 2 (n=9,3) | 13.84 ± 2.71 | 13.13 ± 6.27 |
| Week 4 (n=9,3) | 11.72 ± 3.51 | 13.37 ± 6.05 |
| Week 12 (n=8,3) | 5.80 ± 1.80 | 13.40 ± 6.12 |
Combined assessment of lesion severity and area affected into single score. Body was divided into 4 sections: head, arms, trunk, legs. For each section, percent area of skin involved was estimated: 0=0% to 6=90â€"100%. Severity was estimated by clinical signs: erythema, induration, desquamation; scale: 0= none to 4= maximum. Final PASI = sum of severity parameters for each section\*area score\*weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4) summed over all sections; total possible score range: 0= no disease to 72= maximal disease.
No measurements were reported for this outcome.
Combined assessment of lesion severity and area affected into single score. Body was divided into 4 sections: head, arms, trunk, legs. For each section, percent area of skin involved was estimated: 0= 0% to 6= 90â€"100%. Severity was estimated by clinical signs: erythema, induration, desquamation; scale: 0= none to 4= maximum. Final PASI = sum of severity parameters for each section\*area score\*weight of section (head: 0.1, arms: 0.2, body: 0.3, legs: 0.4) summed over all sections; total possible score range: 0= no disease to 72= maximal disease.
| percent change from baseline | Tofacitinib 10 mg BID | Placebo |
|---|---|---|
| Week 1 (n=9,3) | -18.38 ± 7.52 | -39.61 ± 19.97 |
| Week 2 (n=9,3) | -36.95 ± 8.28 | -48.66 ± 20.28 |
| Week 4 (n=9,3) | -47.39 ± 11.95 | -49.66 ± 19.41 |
| Week 12 (n=8,3) | -71.78 ± 9.63 | -49.13 ± 19.67 |
Combined assessment of lesion severity and area affected into single score; range=0 (no disease) to 72 (maximal disease). Body divided into 4 sections=head, upper/lower limbs, trunk; each area scored by itself and scores combined for final PASI. For each section percent area of skin involved was estimated: 0 (0%) to 6 (90-100%) and severity estimated by clinical signs of erythema, induration, scaling; ranged 0-4: 0=none, 1=slight, 2=moderate, 3=marked, 4=very marked. Final PASI=sum of severity parameters for each section\*area score\*weighing factor (head=0.1, upper limbs=0.2, trunk=0.3, lower limbs=0.4) summed over all sections.
| percentage of participants | Tofacitinib 10 mg BID | Placebo |
|---|---|---|
| Week 1 | 0.00 | 0.00 |
| Week 2 | 0.00 | 33.33 |
| Week 4 | 22.22 | 33.33 |
PGA psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration, and scaling across all psoriatic lesions. PGA of Psoriasis scale ranges from 0 (no psoriasis) to 4 (severe disease). The severity scores of 3 components (erythema, induration, and scaling) are averaged and rounded to the nearest whole number to determine the PGA score.
| units on a scale | Tofacitinib 10 mg BID | Placebo |
|---|---|---|
| Week 1 (n=9,3) | -0.6 ± 0.2 | -0.7 ± 0.3 |
| Week 2 (n=9,3) | -0.8 ± 0.2 | -1.0 ± 0.6 |
| Week 4 (n=9,3) | -1.2 ± 0.3 | -1.0 ± 0.6 |
| Week 12 (n=8,3) | -1.5 ± 0.3 | -1.0 ± 0.6 |
No measurements were reported for this outcome.
PGA psoriasis is scored on a 5-point scale, reflecting a global consideration of the erythema, induration and scaling across all psoriatic lesions. PGA of Psoriasis scale ranges from 0 (no psoriasis) to 4 (severe disease). Response category scores: 0=clear; 1=almost clear; 2=mild; 3=moderate; and 4=severe. The severity scores of 3 components (erythema, induration, and scaling) are averaged and rounded to the nearest whole number to determine the PGA score.
| percentage of participants | Tofacitinib 10 mg BID | Placebo |
|---|---|---|
| Baseline, Moderate (n=9,3) | 88.9 | 66.7 |
| Baseline, Severe (n=9,3) | 11.1 | 33.3 |
| Week 1, Mild (n=9,3) | 44.4 | 33.3 |
| Week 1, Moderate (n=9,3) | 55.6 | 66.7 |
| Week 2, Almost clear (n=9,3) | 11.1 | 33.3 |
| Week 2, Mild (n=9,3) | 44.4 | 0 |
| Week 2, Moderate (n=9,3) | 44.4 | 66.7 |
| Week 4, Almost clear (n=9,3) | 44.4 | 33.3 |
| Week 4, Mild (n=9,3) | 22.2 | 0 |
| Week 4, Moderate (n=9,3) | 33.3 | 66.7 |
| Week 12, Almost clear (n=8,3) | 50.0 | 33.3 |
| Week 12, Mild (n=8,3) | 37.5 | 0 |
| Week 12, Moderate (n=8,3) | 12.5 | 66.7 |
Assessment of BSA with psoriasis was performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The percent surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (ie, the participant's fully extended palm, fingers and thumb together) represents approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region can be used to determine the extent (%) to which a body regions is involved with psoriasis. In each body region, the percent body region surface area with psoriasis is multiplied by the Body Region Weighting (head and neck=10%, upper limbs=5%, trunk \[including axillae and groin\]=3.33% and lower limbs \[including buttocks\]=2.5%). BSA (%)=0.1Sh + 0.2Sh+0.3St+0.4Sl, where S=body region suface area with psoriasis: h=head; u=upper limbs; t=trunk; l=lower limbs.
| % BSA | Tofacitinib 10 mg BID | Placebo |
|---|---|---|
| Baseline (n=9,3) | 34.16 ± 8.12 | 30.50 ± 10.87 |
| Week 1 (n=9,3) | 31.20 ± 7.35 | 24.83 ± 10.43 |
| Week 2 (n=9,3) | 24.20 ± 5.38 | 24.67 ± 10.59 |
| Week 4 (n=9,3) | 19.03 ± 4.70 | 23.33 ± 10.43 |
| Week 12 (n=8,3) | 7.35 ± 3.10 | 23.03 ± 10.50 |
Assessment of BSA with psoriasis was performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The percent surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (ie, the participant's fully extended palm, fingers and thumb together) represents approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region can be used to determine the extent (%) to which a body regions is involved with psoriasis. In each body region, the percent body region surface area with psoriasis is multiplied by the Body Region Weighting (head and neck=10%, upper limbs=5%, trunk \[including axillae and groin\]=3.33% and lower limbs \[including buttocks\]=2.5%). BSA (%)=0.1Sh + 0.2Sh+0.3St+0.4Sl, where S=body region suface area with psoriasis: h=head; u=upper limbs; t=trunk; l=lower limbs.
No measurements were reported for this outcome.
Assessment of BSA with psoriasis was performed separately for 4 body regions: head and neck, upper limbs, trunk (including axillae and groin), and lower limbs (including buttocks). The percent surface area with psoriasis was estimated by means of the handprint method, where the full palmar hand of the participant (ie, the participant's fully extended palm, fingers and thumb together) represents approximately 1% of the total BSA. The number of handprints of psoriatic skin in a body region can be used to determine the extent (%) to which a body regions is involved with psoriasis. In each body region, the percent body region surface area with psoriasis is multiplied by the Body Region Weighting (head and neck=10%, upper limbs=5%, trunk \[including axillae and groin\]=3.33% and lower limbs \[including buttocks\]=2.5%). BSA (%)=0.1Sh + 0.2Sh+0.3St+0.4Sl, where S=body region suface area with psoriasis: h=head; u=upper limbs; t=trunk; l=lower limbs.
| percent change from baseline | Tofacitinib 10 mg BID | Placebo |
|---|---|---|
| Week 1 (n=9,3) | -6.87 ± 4.97 | -27.80 ± 17.46 |
| Week 2 (n=9,3) | -22.51 ± 7.14 | -29.47 ± 19.01 |
| Week 4 (n=9,3) | -35.13 ± 10.45 | -34.93 ± 21.80 |
| Week 12 (n=8,3) | -77.40 ± 11.98 | -37.26 ± 21.53 |
The severity of itch (pruritus) due to psoriasis was assessed using the ISI, a single-item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends. the baseline is defined as the average of all available diary entries before Baseline/Day 1 and the in-clinic measurement on Baseline/day 1. Week 1 is the mean of daily values of study days 2 to 8 and Week 2 is the mean of daily values of study days 9 to 15.
| units on a scale | Tofacitinib 10 mg BID | Placebo |
|---|---|---|
| Baseline (n=9,3) | 6.35 ± 0.89 | 3.46 ± 1.94 |
| Week 1 (n=9,3) | 3.81 ± 0.97 | 3.90 ± 1.73 |
| Week 2 (n=9,3) | 2.45 ± 0.91 | 1.99 ± 0.73 |
| Week 4 (n=9,3) | 1.22 ± 0.57 | 2.67 ± 1.20 |
| Week 12 (n=8,3) | 0.75 ± 0.62 | 6.00 ± 1.53 |
ISI, a single-item, horizontal numeric rating scale. Participants were asked to rate "your worst itching due to psoriasis over the past 24 hours" on a numeric rating scale anchored by the terms "No itching" (0) and "Worst possible itching" (10) at the ends. The baseline is defined as the average of all available diary entries before Baseline/Day 1 and the in-clinic measurement on Baseline/Day 1. Week 1 is the mean of daily values of study days 2 to 8 and Week 2 is the mean of daily values of study days 9 to 15. A negative value indicates an improvement.
| units on a scale | Tofacitinib 10 mg BID | Placebo |
|---|---|---|
| Week 1 (n=9,3) | -2.55 ± 0.59 | 0.45 ± 0.52 |
| Week 2 (n=9,3) | -3.90 ± 0.67 | -1.47 ± 1.31 |
| Week 4 (n=9,3) | -5.13 ± 0.77 | -0.79 ± 2.35 |
| Week 12 (n=8,3) | -5.96 ± 0.99 | 2.54 ± 2.61 |
Target lesions were selected at baseline and followed for the duration of the study. Each target lesion was scored by the investigator on severity of erythema, induration, and scaling according to a 5-point (0 to 4) severity scale with a maximum sum score for a plaque of 12. The TPSS was calculated as the sum of the scores for erythema, induration, and scaling; the score can vary in increments of 1 unit from 0 to 12.
| score on a scale | Tofacitinib 10 mg BID | Placebo |
|---|---|---|
| Baseline (n=9,3) | 8.7 ± 0.6 | 8.3 ± 0.3 |
| Week 1 (n=9,3) | 7.1 ± 0.7 | 7.0 ± 1.2 |
| Week 2 (n=9,3) | 6.0 ± 0.7 | 6.7 ± 1.2 |
| Week 4 (n=9,3) | 4.6 ± 1.1 | 6.7 ± 1.9 |
| Week 12 (n=8,3) | 2.8 ± 1.3 | 6.0 ± 1.7 |
Target lesions were selected at baseline and followed for the duration of the study. Each target lesion was scored by the investigator on severity of erythema, induration, and scaling according to a 5-point (0 to 4) severity scale with a maximum sum score for a plaque of 12. The TPSS was calculated as the sum of the scores for erythema, induration, and scaling; the score can vary in increments of 1 unit from 0 to 12. A negative value indicated improvment.
| percent change from baseline | Tofacitinib 10 mg BID | Placebo |
|---|---|---|
| Week 1 (n=9,3) | -16.69 ± 7.72 | -16.67 ± 11.02 |
| Week 2 (n=9,3) | -29.78 ± 8.39 | -20.83 ± 11.02 |
| Week 4 (n=9,3) | -47.55 ± 12.40 | -20.83 ± 20.83 |
| Week 12 (n=8,3) | -67.28 ± 15.17 | -29.17 ± 18.16 |
Collected over Adverse events (AEs) were reported from the time of informed consent through and including 28 calendar days after the last administration of the investigational product.. Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tofacitinib 10 mg BID | — | 0/9 (0%) | 2/9 (22.2%) |
| Placebo | — | 1/3 (33.3%) | 1/3 (33.3%) |
| Event | Tofacitinib 10 mg BID | Placebo |
|---|---|---|
| CholelithiasisHepatobiliary disorders | 0/9 | 1/3 |
| Event | Tofacitinib 10 mg BID | Placebo |
|---|---|---|
| Gravitational oedemaGeneral disorders | 0/9 | 1/3 |
| LymphadenopathyBlood and lymphatic system disorders | 1/9 | 0/3 |
| NasopharyngitisInfections and infestations | 1/9 | 0/3 |
| PharyngitisInfections and infestations | 1/9 | 0/3 |
| Tooth infectionInfections and infestations | 1/9 | 0/3 |
| SyncopeNervous system disorders | 1/9 | 0/3 |
| PsoriasisSkin and subcutaneous tissue disorders | 1/9 | 0/3 |
| Age, Continuous(Years) | Tofacitinib 10 mg BID | Placebo | Total |
|---|---|---|---|
| Mean | 45.2 ± 11.3 | 46.7 ± 21.5 | 45.6 ± 13.3 |
| Sex: Female, Male(Participants) | Tofacitinib 10 mg BID | Placebo | Total |
|---|---|---|---|
| Female | 2 | 2 | 4 |
| Male | 7 | 1 | 8 |
The record gives a start of Mar 2013, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2015, 1 year 5 months after primary completion. A results delay was requested in Jan 2015.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tofacitinib